Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Genelux Corporation
Genelux Corporation
Merck Sharp & Dohme LLC
AstraZeneca
Merck Sharp & Dohme LLC
BioNTech SE
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Huazhong University of Science and Technology
Air Force Military Medical University, China
SWOG Cancer Research Network
National Cancer Institute (NCI)